The last few years have seen a sharp increase in cell and gene therapy (CGT) clinical trials and products coming to market. Industry leaders believe 2024 could be a pivotal year for the field, resulting in more approvals for personalized medicines than ever before. That’s promising news for patients who may have run out of treatment options – but scaling for commercialization doesn’t come without challenges.
Those challenges – and how to overcome them – is exactly what this must-watch webinar covers. Tune in for expert insights on managing the complexities of CGT commercialization from QuickSTAT’s Michael Sweeney, Global Head of Strategy for CGT & DTP, Cardinal Health’s Joel Wayment, Vice President, 3PL Services and Fran Gregory, Vice President Emerging Therapies, PharmD, MBA and TrakCel’s Akshay Peer, Senior Vice President, Product, (Ph.D.).